These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 16708063)
1. Graft-versus-tumor effects on murine mammary carcinoma in a model of nonmyeloablative haploidentical stem cell transplantation. Vanclée A; van Gelder M; Schouten HC; Bos GM Bone Marrow Transplant; 2006 Jun; 37(11):1043-9. PubMed ID: 16708063 [TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
5. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators. Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627 [TBL] [Abstract][Full Text] [Related]
6. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482 [TBL] [Abstract][Full Text] [Related]
7. Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI. Kummar S; Ishii A; Yang HK; Venzon DJ; Kim SJ; Gress RE Biol Blood Marrow Transplant; 2001; 7(1):25-30. PubMed ID: 11215695 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy by allogeneic stem cell transplantation. Ringdén O Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940 [TBL] [Abstract][Full Text] [Related]
11. Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. Frings PW; Van Elssen CH; Wieten L; Matos C; Hupperets PS; Schouten HC; Bos GM; van Gelder M Breast Cancer Res Treat; 2011 Dec; 130(3):773-81. PubMed ID: 21274621 [TBL] [Abstract][Full Text] [Related]
12. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice]. Wang SB; Guo KY; Hu DM; Yin B Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606 [TBL] [Abstract][Full Text] [Related]
13. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251 [TBL] [Abstract][Full Text] [Related]
14. [Role of paternal veto cells in preventing graft-versus-host disease after HLA-haploidentical stem cell transplantation in mice]. Wang SB; Guo KY; Hu DM Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):79-81. PubMed ID: 18227034 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic cell therapy for a murine mammary carcinoma. Morecki S; Yacovlev E; Diab A; Slavin S Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499 [TBL] [Abstract][Full Text] [Related]
16. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Li JM; Gorechlad J; Larsen CP; Waller EK Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205 [TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Saito TI; Rubio MT; Sykes M Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820 [TBL] [Abstract][Full Text] [Related]
18. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020 [TBL] [Abstract][Full Text] [Related]
19. [Establishment of a rhesus haploidentical hematopoietic stem cell and mesenchymal stem cell transplantation model by nonmyeloablative conditioning]. Liu LH; Sun QY; Hu KX; Huang YJ; Fan CB; Sun Z; Yao B; Guo M; Zhao CH; Ai HS Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):385-8. PubMed ID: 16251015 [TBL] [Abstract][Full Text] [Related]
20. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]